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OBJECTIVE — To compare the ability of two starter insulin regimens to achieve glycemic
control in a large, ethnically diverse population with type 2 diabetes.
RESEARCH DESIGN AND METHODS — During the initiation phase of the DURABLE
trial, patients were randomized to a twice-daily lispro mix 75/25 (LM75/25; 75% lispro prota-
mine suspension, 25% lispro) (n  1,045) or daily glargine (GL) (n  1,046) with continuation
of prestudy oral antihyperglycemic drugs.
RESULTS — Baseline A1C was similar (LM75/25: 9.1  1.3%; GL: 9.0  1.2%; P  0.414).
At 24 weeks, LM75/25 patients had lower A1C than GL patients (7.2  1.1 vs. 7.3  1.1%, P 
0.005), greater A1C reduction (–1.8  1.3 vs. –1.7  1.3%, P  0.005), and higher percentage
reaching A1C target 7.0% (47.5 vs. 40.3%, P  0.001). LM75/25 was associated with higher
insulindose(0.470.23vs.0.400.23units kg
1 day
1,P0.001)andmoreweightgain
(3.6  4.0 vs. 2.5  4.0 kg, P  0.0001). LM75/25 patients had a higher overall hypoglycemia
ratethanGLpatients(28.041.6vs.23.140.7episodes pt
1 year
1,P0.007)butlower
nocturnal hypoglycemia rate (8.9  19.3 vs. 11.4  25.3 episodes   pt
1   year
1, P  0.009).
Severe hypoglycemia rates were low in both groups (LM75/25: 0.10  1.6 vs. GL: 0.03  0.3
episodes   pt
1   year
1, P  0.167).
CONCLUSIONS — ComparedwithGL,LM75/25resultedinslightlylowerA1Cat24weeks
and a moderately higher percentage reaching A1C target 7.0%. Patients receiving LM75/25
experienced more weight gain and higher rates of overall hypoglycemia but lower rates of
nocturnal hypoglycemia. Durability of regimens will be evaluated in the following 2-year main-
tenance phase.
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I
n patients with type 2 diabetes inade-
quately controlled on oral antihyper-
glycemic drugs (OADs), therapeutic
optionsincludetheadditionofonce-daily
basal or twice-daily premixed insulin (1–
8). Previous studies comparing these two
insulin initiation strategies (6–8) have
noted greater A1C reduction with analog
mixturetherapy;however,thesestudiesdid
not use the same oral agents in both arms
and therefore compared treatment strate-
gies rather than speciﬁc insulin regimens.
Few large studies have compared
starter insulin regimens in combination
with OADs. One such study, Treating To
Target in Type 2 Diabetes (4-T), is an on-
going3-yeartrialevaluatingthesafety,ef-
ﬁcacy, and need to intensify therapy
among analog insulin regimens (basal,
rapid acting, or premixed) used in com-
bination with dual OAD therapy in over
700 insulin-naïve patients with type 2 di-
abetes from the U.K. and Ireland (9). The
present study, DURABLE (assessing
DURAbility of Basal versus Lispro mix
75/25 insulin Efﬁcacy), was designed to
studytheefﬁcacy,safety,anddurabilityof
two common insulin initiation regimens:
twice-daily insulin lispro mixture 75/25
(LM75/25; Humalog Mix 75/25: 75% in-
sulin lispro protamine suspension, 25%
lispro) versus once-daily insulin glargine
(GL; Lantus insulin glargine [rDNA ori-
gin] injection) within the context of con-
tinued OADs. The results of the 24-week
initiation phase, presented here, will pro-
vide the ﬁrst comparison of safety and ef-
ﬁcacy for these two regimens in a large,
ethnically diverse population. The ongo-
ing, 2-year maintenance phase will evalu-
ate the length of time each starter insulin
regimen is able to maintain A1C goals
(i.e., regimen durability).
RESEARCH DESIGN AND
METHODS— A detailed description
of the DURABLE study design has previ-
ously been published (10). The 24-week
initiation phase was a randomized, open-
label, parallel trial conducted at 242 cen-
ters in 11 countries (Argentina, Australia,
Brazil, Canada, Greece, Hungary, India,
theNetherlands,Romania,Spain,andthe
U.S.) between December 2005 and July
2007. The trial was conducted in accor-
dance with the International Conference
on Harmonization Guidelines for Good
Clinical Practice and the Declaration of
Helsinki (11); all patients provided writ-
ten informed consent.
The trial enrolled 2,091 insulin-naïve
patientswithtype2diabetes,aged30–80
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OADs for 90 days (minimum doses:
1,500 mg/day metformin, one-half maxi-
mum daily dose sulfonylurea [SFU], 30
mg/daypioglitazone,or4mg/dayrosiglit-
azone).Patientswereexcludediftheyhad
a history of scheduled long-term insulin
use; recent use of other antihyperglycemic
agents; BMI 45 kg/m
2; recent history of
severehypoglycemia;signiﬁcantconcom-
itant hematologic, oncological, renal, car-
diac, hepatic, or gastrointestinal disease;
recent systemic steroid use; or were preg-
nant or breastfeeding. A1C was measured
centrally by Covance Laboratories. In the
2 weeks preceding the 24-week visit, pa-
tients recorded three seven-point self-
monitored plasma glucose (SMPG)
proﬁles consisting of three premeal mea-
surements (ﬁrst measurement fasting),
three 2-h postprandial measurements,
and a 3:00 A.M. measurement (Roche Ac-
tive or Roche Aviva meters).
Study medications and treatments
Eligible patients were randomly assigned
to one of two treatment arms by stratiﬁed
randomization through an interactive
voice-response system. Patients were ran-
domized by country and stratiﬁed within
country based on SFU and thiazolidine-
dione (TZD) use. Patients received
LM75/25 twice daily before morning and
evening meals or GL once daily before
morning or evening meal or at bedtime.
Both insulin therapies were added to pa-
tients’ prestudy OADs. Following random-
ization, patients were required to maintain
prestudy OADs at current dosages.
The minimum starting dose was 10
units twice daily for LM75/25 and 10
units once daily for GL. Insulin dose ad-
justments were made to achieve a target
A1C goal of 6.5%, utilizing regimen-
speciﬁc, insulin dose titration algorithms
(12,13)(onlineappendixTableA1[avail-
able at http://care.diabetesjournals.org/
cgi/content/full/dc08-2117/DC1]). Patients
monitored plasma glucose at least twice
daily (before morning and evening meals).
Each patient’s dose was assessed and ad-
justed frequently (at a minimum, once
weekly for the ﬁrst 6 weeks, once every 2
weeks for the next 6 weeks, and then once
every 6 weeks to the 24-week end point).
An electronic case report form–based sys-
tem encouraged titration per protocol, and
adatamonitoringcommitteemonitoredin-
sulin dose adjustments to ensure patient
safety and provide investigators feedback
regarding appropriate adherence to dosing
algorithms.
Safety was monitored throughout the
study, and the occurrence and nature of
serious adverse events (SAEs) were re-
corded. Hypoglycemia was predeﬁned as
a plasma glucose value 70 mg/dl (3.9
mmol/l)orsymptomsthatthepatienttyp-
ically associated with hypoglycemia. Epi-
sodesofhypoglycemiathatoccurredafter
bedtime and before the morning meal/
insulin dose were considered nocturnal.
Severe hypoglycemia was deﬁned as an
episoderequiringassistancefromanother
person for treatment with oral carbohy-
drate, intravenous glucose, or glucagon
(14). SAEs were deﬁned as events result-
ing in death, life-threatening experience,
hospitalization, or persistent or signiﬁ-
cant disability.
Figure 1—Flow of patients through the initiation phase (ﬁrst 24 weeks) of the DURABLE trial.
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The primary efﬁcacy measure was A1C at
end point (last observation carried for-
ward [LOCF] to 24 weeks). Secondary
outcome measures included change in
A1C from baseline to end point, A1C at
eachvisit,percentageofpatientswithend
point A1C 7.0% and 6.5%, seven-
point SMPG proﬁles, weight change from
baseline, total daily insulin (TDI) dose at
end point, and incidence and rate of hy-
poglycemic episodes.
Statistical methods
We calculated that 1,000 subjects per
groupwouldprovide97%powertode-
tect a difference of 0.2% in 24-week end
point A1C between treatment groups
(two-sided 0.05 assuming a 1.1% SD
and a drop-out rate of 10%). The sample
size calculation was primarily based on
the maintenance-phase primary objec-
tive. The analyses of initiation-phase data
were prespeciﬁed and performed with
LOCF method on the intent-to-treat pop-
ulation who had at least one postbaseline
assessment. The primary outcome (end
point A1C) was analyzed by ANCOVA
with treatment, baseline A1C, country,
and SFU and TZD use as covariates. Sec-
ondary outcomes (SMPG, TDI, weight
change, hypoglycemia rate, and severe
hypoglycemia rate) were analyzed using
ANCOVA with treatment, country, and
SFU and TZD use as covariates. Percent-
age of patients achieving A1C goals was
analyzed using Cochran-Mantel-Haens-
zel statistic controlling for country, TZD
use, and SFU use. Categorical safety vari-
ables were compared between groups
with a Fisher’s exact test.
RESULTS
Patient disposition and baseline
characteristics
Of 2,091 patients randomized, 1,045
were assigned to LM75/25 and 1,046 to
GL. Approximately 86% (n  900) of pa-
tients in the LM75/25 group and 88%
(n  918) in the GL group completed the
trial; reasons for discontinuation are sum-
marized in Fig. 1. There was no signiﬁcant
differencebetweenoveralldiscontinuations
or any individual reported reason for dis-
continuation between groups (P0.05 for
all comparisons).
At baseline, treatment groups were
similar with regard to demographic, an-
thropometric, and disease characteristics
(Table 1). The patient population was
63% non-Hispanic Caucasian, 2% East/
Southeast Asian, 13% Western Asian,
12% Hispanic, 6% African descent, and
3%otherracial/ethnicorigin.Overall,the
mean age was 57 years, 53% of patients
weremen,BMIwas32kg/m
2,averagedu-
rationofdiabeteswas9.5years,andmean
A1C was 9.0  1.3%. Approximately
92% (n  1,917) of all patients were on
an SFU, with the most common OAD
combination being metformin plus SFU
(64%; n  1,339).
Glycemic control
The change in A1C from baseline to end
point was greater for the LM75/25 group
compared with the GL group (–1.8  1.3
vs. –1.7  1.3%, P  0.005) (Fig. 2A).
Mean A1C decreased in both groups with
therapy (P  0.0001 for comparison of
baseline to 24 weeks) (Fig. 2B). At end
point, A1C was lower for LM75/25 com-
pared with glargine (7.2  1.1 vs. 7.3 
1.1%, P  0.005). After adjusting for
baseline A1C, country of origin, SFU use,
and TZD use, end point A1C (least-
squares mean  SE) values were 7.0 
0.1%forLM75/25and7.10.1%forGL
(P  0.005). As shown in Fig. 2C,a
higher percentage of patients in the
LM75/25 group were able to reach target
A1C 7.0% by end point compared with
the GL group (47.5 vs. 40.3%, P 
0.001). There was no difference between
groups in the percentage of patients who
achieved A1C 6.5% (LM75/25 24.6%,
GL 22.2%; P  0.174).
Comparison of baseline and end
point seven-point SMPG proﬁles (online
appendix Fig. A1) showed that therapy
with either LM75/25 or GL lowered
plasma glucose values at all time points
(P  0.0001). At end point, fasting
plasma glucose was higher in the
LM75/25 group than in the GL group
(134  35 vs. 122  33 mg/dl, P 
0.001). Patients in the LM75/25 group
had lower 2-h postprandial plasma glu-
cose after morning (167  49 vs. 172 
49 mg/dl, P  0.05) and evening (163 
47vs.17649mg/dl,P0.001)meals,
as well as lower premeal plasma glucose
before the noon meal (130  42 vs.
137  44 mg/dl, P  0.001). There were
no differences between therapies for
plasma glucose values at the noon 2-h
postprandial, evening premeal, or 3:00
A.M. time points.
Insulin dose and weight gain
At end point, the TDI dose (mean  SD)
was higher for patients in the LM75/25
group than in the GL group (0.47  0.23
vs. 0.40  0.23 units/kg, P  0.001). Pa-
tients on LM75/25 gained more weight
than did patients on GL (3.6  4.0 vs.
2.5  4.0 kg, P  0.001).
Table 1—Baseline demographics and characteristics of randomized patients
LM75/25 group GL group P
n 1,045 1,046
Age (years) 57  10 57  10 0.264
Male (%) 552 (52.8) 552 (52.8) 0.979
Race/ethnicity
Caucasian 651 (62.3) 668 (63.9) 0.469
East/Southeast Asian 18 (1.7) 27 (2.6) 0.228
Western Asian 139 (13.3) 136 (13.0) 0.846
Hispanic 136 (13.0) 116 (11.1) 0.180
Black/African descent 62 (5.9) 70 (6.7) 0.529
Other 39 (3.7) 29 (2.8) 0.221
Weight (kg) 89  21 88  21 0.497
BMI (kg/m
2) 32  63 2  6 0.917
Diabetes duration (years) 9.7  6.3 9.3  5.9 0.109
A1C (%) 9.1  1.3 9.0  1.2 0.414
Fasting plasma glucose (mg/dl) 193  53.2 196  55.1 0.179
Fasting plasma glucose (mmol/l) 10.7  3.0 10.9  3.1 0.179
Concomitant OADs at study entry
MET/SFU/TZD 233 (22.3) 225 (21.5) 0.689
MET/SFU 674 (64.5) 665 (63.6) 0.724
MET/TZD 81 (7.8) 78 (7.5) 0.814
SFU/TZD 51 (4.9) 69 (6.6) 0.088
Data are means  SD or n (%).
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At end point, a higher (P  0.016) per-
centage of patients on LM75/25 experi-
enced at least one episode of hypoglycemia
(incidence of overall hypoglycemia) than
patients on GL (Table 2). Additionally,
patients on LM75/25 had a higher (P 
0.007) rate of overall hypoglycemia than
did their GL-treated counterparts. Pa-
tients on LM75/25 had a lower (P 
0.009) rate of nocturnal hypoglycemia
compared with patients on GL (Table 2).
The majority of patients in the GL treat-
ment group administered their daily dose
before breakfast (n  396; 39%), before
the evening meal (n  139; 14%), or at
bedtime (n  458; 45%); among these
groups,nocturnalhypoglycemiaratesdid
not differ between groups (P  0.05 for
all comparisons). There were no statisti-
cally signiﬁcant differences between
groups in the incidence or rate of severe
hypoglycemia (Table 2). As shown in Fig.
2D,theobservedmeanhypoglycemiarate
continued to increase in association with
increasing insulin dose through week 12
for both treatment groups. After week 12,
the overall hypoglycemia rate compara-
tively decreased, even with gradual con-
tinued upward titration of insulin dose.
Safety
Overall, 65 (6.2%) patients in the
LM75/25groupand45(4.3%)patientsin
the GL group experienced at least one
SAE (P  0.051); the percentage of car-
diovascular system–related SAEs was
similarbetweentreatmentgroups(LM75/
25: 29%; GL: 26%; P  0.716). There
were 15 adverse events (AEs) leading to
discontinuation in the LM75/25 group
and 6 AEs in the GL group (P  0.077)
(Fig. 1). Five deaths occurred in the
LM75/25 group and one death occurred
in the GL group (P  0.218) (Fig. 1). In
addition, an SAE in two GL-treated pa-
tients led to death after discontinuation
from the study.
CONCLUSIONS — The24-weekini-
tiationphaseoftheDURABLEstudycom-
pared two common starter insulin
regimens(LM75/25twicedailyversusGL
once daily) in a large multinational pop-
Figure 2—A: Change in A1C from baseline to end point for patients treated with LM75/25 (f) versus glargine ( ). **P  0.01. B: A1C values at
each visit for patients treated with LM75/25 (Œ) versus glargine ( ). **P  0.01; †P  0.001. C: Percent of patients achieving A1C target 7.0%
at end point for patients treated with LM75/25 (f) versus glargine ( ). †P  0.001. D: Observed mean overall hypoglycemia rate (episodes   pt
1  
year
1) and TDI dose (units/kg) at each visit between 6 and 24 weeks of therapy for patients treated with LM75/25 (Œ, hypoglycemia rate; ‚, TDI) or
glargine (f, hypoglycemia rate;  , TDI).
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who were concurrently receiving two to
three OADs, including SFUs. Although
both regimens demonstrated signiﬁcant
A1C reduction from baseline, some im-
portant differences were observed be-
tween therapies. Compared with GL,
LM75/25 therapy resulted in slightly
lower end point A1C and a moderately
higher percentage of patients reaching
A1C target of 7.0% but with more
weightgainandhigherratesofoverallhy-
poglycemia. Nocturnal hypoglycemia
rateswerelowerwithLM75/25,andthere
were no differences in the frequency or
rate of severe hypoglycemia between the
groups.
The rationale for use of premixed in-
sulinanalogsinthemanagementoftype2
diabetes is based on the need for basal
and postprandial glucose–lowering activ-
ity to more closely mimic physiological
insulin secretion. In the DURABLE study,
LM75/25 demonstrated better postpran-
dial glycemic control after the morning
and evening meals compared with GL
(with over 90% SFU use across treatment
groups). There is evidence that improve-
mentinpostprandialglycemicexcursions
may be beneﬁcial, as elevated postpran-
dial glucose levels have been suggested as
an independent risk factor for many dia-
betes-related complications, including
macrovascular disease (15–19). Addi-
tionally,atA1Cvaluesapproachinglower
targeted goals, the need to address post-
prandial glucose control becomes in-
creasingly important (20).
Efﬁcacy ﬁndings from our study are
consistent with those described for the
ﬁrst phase of the 4-T study (9), which
reported 1-year results for three different
analog insulin initiation therapies (basal,
biphasic premixed, and prandial). Both
studies compared insulin initiation regi-
mens in the setting of continued prestudy
OADs, including SFU. The 24-week initi-
ation phase of the DURABLE study eval-
uated a similar question to the 4-T study,
comparinguseofbiphasicandbasalinsu-
lin as starter insulin therapy but did so in
a larger, more diverse population. In con-
trast to the 4-T study, which allowed for
the use of an additional insulin formula-
tionasrescuetherapyduringtheﬁrstyear
of treatment, the initiation phase of the
DURABLE study did not allow rescue
therapy.
The DURABLE study, like the 4-T
study, required insulin dose titration ac-
cording to prespeciﬁed algorithms. De-
spite this, only 40–50% of DURABLE
patients, regardless of treatment regimen,
achieved the American Diabetes Associa-
tion–recommended A1C target of 7.0%;
though these results were more favorable
than the 1-year percent to target A1C
7.0%inthe4-Tstudy(biphasic:41.7%;
basal: 27.8%). In the DURABLE study,
Table 2—Incidence and rate of hypoglycemia*
LM75/25 group GL group P
Hypoglycemia incidence
Overall 586 (57.1) 530 (51.8) 0.016
Documented symptomatic (plasma glucose 70 mg/dl 3.9 mmol/l	) 454 (44.2) 345 (33.7) 0.001
Documented symptomatic (plasma glucose 60 mg/dl 3.3 mmol/l	) 388 (37.2) 295 (28.2) 0.001
Documented symptomatic (plasma glucose 50 mg/dl 2.8 mmol/l	) 210 (20.1) 120 (11.5) 0.001
Documented asymptomatic (plasma glucose 70 mg/dl 3.9 mmol/l	) 265 (25.8) 289 (28.2) 0.194
Nocturnal 348 (33.9) 351 (34.3) 0.834
Severe† 22 (2.1) 12 (1.2) 0.080
Hypoglycemia rate (episode   pt
1   year
1)
Overall
Median (interquartile range) 8.7 (0.0–42.1) 7.0 (0.0–27.2) 0.007
Observed mean 28.0 23.1 0.007
Documented symptomatic (plasma glucose 70 mg/dl 3.9 mmol/l	)
Median (interquartile range) 0.0 (0.0–20.9) 0.0 (0.0–8.9) 0.001
Observed mean 17.83 11.80 0.001
Documented symptomatic (plasma glucose 60 mg/dl 3.3 mmol/l	)
Median (interquartile range) 0.0 (0.0–31.3) 0.0 (0.0–13.0) 0.006
Observed mean 23.00 18.07 0.006
Documented symptomatic (plasma glucose 50 mg/dl 2.8 mmol/l	)
Median (interquartile range) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.001
Observed mean 15.30 9.29 0.001
Documented asymptomatic (plasma glucose 70 mg/dl 3.9 mmol/l	)
Median (interquartile range) 0.0 (0.0–7.3) 0.0 (0.0–7.9) 0.117
Observed mean 7.13 8.48 0.117
Nocturnal
Median (interquartile range) 0.0 (0.0–8.7) 0.0 (0.0–9.9) 0.009
Observed mean 8.9 11.4 0.009
Severe†
Median (interquartile range) 0.00 (0.0–0.0) 0.0 (0.0–0.0) 0.167
Observed mean 0.10 0.03 0.167
Data are n (%) or median (interquartile range), unless otherwise indicated. *Hypoglycemia was recorded any time a patient experienced symptoms of hypoglycemia
or had an SMPG 70 mg/dl (3.9 mmol/l), and the event was deemed severe if it required assistance. For all nonsevere hypoglycemia, values were calculated at end
point (using LOCF) for the period between the previous ofﬁce visit and end point ofﬁce visit. †For severe hypoglycemia, incidence and rate were calculated over the
entire study duration due to the rare occurrence of severe hypoglycemia.
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curred during the ﬁrst 12 weeks, which
corresponded to the phase of the most
frequent insulin dose adjustments and
the largest increase in total daily dose.
This highlights the need for ongoing as-
sessment and adjustment of insulin doses
over time in an effort to improve and
maintain glucose control while managing
the risk of hypoglycemia. The majority of
DURABLEinvestigativesiteswereincom-
munity-based clinics, and these real-
world ﬁndings may, in part, reﬂect the
challenge of limited time for plasma glu-
cose review and adjustment of insulin
regimens, as well as the treatment barrier
of symptomatic hypoglycemia.
An increased occurrence of hypogly-
cemia with the combination of insulin
and SFU could have limited insulin dose
adjustments in both studies. This ratio-
nale is suggested by a TDI dose of 0.40–
0.47 units   kg
1   day
1 for patients in
our study and, similarly, a TDI dose of
0.49–0.53 units   kg
1   day
1 in basal
and biphasic insulin-treated patients in
the 4-T study. This is somewhat lower
than the reported TDI dose in previous
insulin initiation studies using basal or
premix insulin without concomitant SFU
(7,8).
Additionally, in the DURABLE study,
investigatorswereinstructedtoadjustthe
insulin dose to prevent recurrent hypo-
glycemiabutwerenotallowedtoalterthe
SFU dose. This was done in an effort to
control for factors impacting medication-
induced glycemic control other than the
two speciﬁc insulin regimens under in-
vestigation. Thus, when patients experi-
enced hypoglycemia in the setting of
improving glucose control, physicians
maynothavehadtheﬂexibilityneededto
further individualize the insulin plus
OAD regimen. In clinical practice, it may
be more practical to allow adjustment of
eitherinsulindoseorSFUinordertocon-
tinue to optimize glycemic control while
limiting hypoglycemia.
In light of recent published studies
reporting on cardiovascular outcomes in
patients with type 2 diabetes (21,22), it is
important to note that this study was not
designed to compare these end point
measures (e.g., no stratiﬁed randomiza-
tion based on cardiovascular risk factors,
no data collection of past medical history
or concomitant nondiabetes medications,
and no adjudication of events). With-
drawals due to AEs, SAEs, and deaths did
not differ signiﬁcantly between treatment
groups, even in this large study popula-
tion; however, there were numerically
more events in the LM75/25 group. Be-
cause of the aforementioned trial design
limitations, it is difﬁcult to draw substan-
tive conclusions from these observations
other than the importance of considering
the need for risk factor assessment when
designing future clinical trials in type 2
diabetes.
Inapredominatelycommunity-based
setting, in 11 countries across ﬁve conti-
nents, type 2 diabetic patients initiating
insulin with either twice-daily LM75/25
or once-daily GL, in combination with
OADs, had a clinically meaningful reduc-
tion of A1C. At 24 weeks, LM75/25 dem-
onstrated modestly greater efﬁcacy, with
a 0.1% greater absolute A1C reduction
and 7.2% more patients treated to reach
the American Diabetes Association–
recommended A1C goal of 7.0% in the
setting of more overall hypoglycemia but
less nocturnal hypoglycemia. Clinicians
will need to weigh the signiﬁcance of
these ﬁndings within their own algo-
rithms of care as they strive to achieve
glycemic goals and meet the standards of
diseasemanagementprogramsevaluating
quality of care (17,23,24). An important
unanswered question—the long-term
durability of starter insulin therapy—is
being evaluated in the ongoing 2-year
maintenance phase of the DURABLE
study.
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